Skip to main content
ALCAlcon Inc.Hold5.1·$68.33-1.91%
HoldModerate Confidence
Investment thesis

Alcon's confirmed price downtrend and a put-to-call ratio of 3.70 reflect significant near-term bearish sentiment — though rising analyst estimates, 19% upside to the consensus target, and strong cash conversion suggest the setup could improve materially if the earnings momentum visible in three of the past four quarters persists.

Thesis pillars

  • Death Cross Confirmed DowntrendStable
  • Elevated Put Call Ratio Bearish PositioningStable
  • Rising Estimates Offset Weak GrowthStable
  • +1 more pillar — see the Why tab for full reasoning

Full reasoning →

Open full analysis

Alcon Inc. (ALC) Stock Analysis

Recovery setup

HoldModerate Confidence

Healthcare · Medical Instruments & Supplies

Hold if already holding. Not a fresh buy at $68.33, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -2.9%/30d (confirmed downtrend).

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and... Read more

$68.33+15.8% A.UpsideScore 5.1/10#19 of 32 Medical Instruments & Supplies
QualityF-score8 / 9FCF yield3.61%
IncomeYield0.52%(5y avg 0.29%)Payout20.39%sustainable
Stop $65.23Target $79.13(analyst − 10%)A.R:R 2.4:1
Analyst target$87.92+28.7%15 analysts
$79.13our TP
$68.33price
$87.92mean
$107

Hold if already holding. Not a fresh buy at $68.33, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -2.9%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 56. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Score 5.1/10, moderate confidence.

Passes 7/9 gates (positive momentum, favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 36d clear, semi cycle peak clear, materials cycle peak clear). Suitability: moderate.

news + 30-day 8-K events · 5-min refresh

Recent developments

updated 2026-07-07
TrendMatrix Research · upcoming catalyst calendar

Upcoming dated catalysts

Mon, Aug 10, 202636d to earnings· next earnings call

Thesis

Rewards
Strong earnings beat streak (3/4)
Earnings estimates trending UP
Risks
Weak growth
Below 200-MA, MA slope -2.9%/30d (confirmed downtrend)

Key Metrics

P/E (TTM)41.7
P/E (Fwd)17.5
Mkt Cap$34.0B
EV/EBITDA16.2
Profit Mgn7.7%
ROE3.7%
Rev Growth9.4%
Beta0.70
Dividend0.52%
Rating analysts18

Quality Signals

Piotroski F8/9MoatNarrow

Options Flow

P/C1.04bearish
IV42%normal

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Rating Breakdown

3 floor-breakers

Growth below the gate floor. Component breakdown shows what dragged the score down.static

Earnings Growth
0.0
Revenue Growth
4.8

Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static

Value Rank
4.2
Growth Rank
4.3
Quality Rank
6.1

Technicals below the gate floor. Component breakdown shows what dragged the score down.static

Bollinger
2.1
Support Resistance
2.4
52w Position
4.8
Gap
6.0
GatesMomentum 5.2<5.5 (soft — BUY_NOW allowed but watch)Death cross (50MA < 200MA)Momentum 5.2>=4.5A.R:R 2.4 ≥ 1.5Insider activity: OKNo SEC red flagsEARNINGS PROXIMITY 36d clearSEMI CYCLE PEAK CLEARMATERIALS CYCLE PEAK CLEARRecoverySuitability: Moderate
RSI
56 · Neutral
20D MA 50D MA 200D MADEATH CROSSSupport $63.81Resistance $69.75

Price Targets

$65
$79
A.Upside+15.8%
A.R:R2.4:1

Position Sizing

ConvictionNone
Suggested %0.5%
Max %1%
RegimeSteady

Risk Alerts

! NEWS_MOD=+1: SELL_IF_HOLDING → HOLD_IF_HOLDING

Earnings

B
B
B
M
3/4 beats
Next Earnings2026-08-10 (36d)

Verdict History

reverse chrono — latest first
Loading history...
Verdicts are recorded on every nightly pipeline run. Rows capture transitions (verdict flips, score deltas ≥0.3, entry/TP/SL changes). Rows with a ▶ can be expanded to see the change reason. Aggregate cohort performance is tracked in the recommendation ledger.
Frequently Asked Questions
Is ALC stock a buy right now?

Hold if already holding. Not a fresh buy at $68.33, but acceptable to hold if already in. Reasons: Weak growth; Below 200-MA, MA slope -2.9%/30d (confirmed downtrend). Chart setup: Death cross but MACD improving, RSI 56. Multiple concerning factors. Consider reducing position. | News modifier +1 (SELL_IF_HOLDING → HOLD_IF_HOLDING) Target $79.13 (+15.8%), stop $65.23 (−4.8%), A.R:R 2.4:1. Score 5.1/10, moderate confidence.

What is the ALC stock price target?

Take-profit target: $79.13 (+15.8% upside). Target $79.13 (+15.8%), stop $65.23 (−4.8%), A.R:R 2.4:1. Stop-loss: $65.23.

What are the risks of investing in ALC?

Weak growth; Below 200-MA, MA slope -2.9%/30d (confirmed downtrend).

Is ALC overvalued or undervalued?

Alcon Inc. trades at a P/E of 41.7 (forward 17.5). TrendMatrix value score: 5.7/10. Verdict: Hold.

What do analysts say about ALC?

18 analysts cover ALC with a consensus score of 4.0/5. Average price target: $88.

What does Alcon Inc. do?Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates...

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products worldwide. The company operates through two segments, Surgical and Vision Care. It offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. The company's cataract products include Unity CS, LenSx laser system, Verion reference unit and Verion digital marker, ARGOS biometer, SMARTCATARACT health platform, NGENUITY 3D visualization system, LuxOR surgical ophthalmic microscope, and ORA system for intra-operative measurements; ADI cloud-based platform; and implantable products, including monofocal, Toric, and Presbyopia-Correcting IOLs, as well as delivery systems, such as AutonoMe and UltraSert. In addition, it provides Custom Pak surgical procedure packs vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, Grieshaber, MIVS instruments; scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit probes; and refractive surgery products, including WaveLight and Contoura Vision used for LASIK refractive procedure. Further, the company offers daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, ocular allergies, glaucoma, and contact lens care, as well as ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.

Related stocks: WST (West Pharmaceutical Services, I) · RMD (ResMed Inc.) · NVST (Envista Holdings Corporation) · TFX (Teleflex Incorporated) · MMSI (Merit Medical Systems, Inc.)
Home Stocks ALC

Latest news

Latest News

GuruFocus69d ago
Newser69d ago
Quiver Quantitative63d ago
Marketscreener.com68d ago
MSN68d agoMerger Acquisition
Yahoo Finance65d ago
DirectorsTalk Interviews71d ago
Benzinga14h agoProduct
Benzinga58d ago
Benzinga60d agoAnalyst
Benzinga61d agoAnalyst
Benzinga61d ago
Benzinga61d ago
Benzinga62d agoAnalyst
Benzinga62d agoEarnings
Benzinga62d agoAnalyst
Benzinga63d agoEarnings
Benzinga63d agoEarnings
Benzinga63d agoEarnings